I am currently creating novel, urgently needed receptor binding data for β-lactam antibiotics to inform novel combination therapies which can combat multidrug-resistant bacterial ‘superbugs’. Within Dr. Juergen Bulitta’s team, I am employing a translational approach which leverages these molecular insights to inform innovative antibiotic combination dosing strategies for latest dynamic in vitro and animal infection models.
Ultimately, these data uniquely inform translational Quantitative and Systems Pharmacology (QSP) models to rationally optimize patient therapies. I serve as a lead modeler for the application of such QSP models on an FDA project and I am developing population pharmacokinetic / pharmacodynamic models for cystic fibrosis patients based on data from clinical studies.
While completing my Ph.D. in Pharmaceutics from The Ohio State University, I acquired a wide range of experimental skill sets in the areas of drug development, molecular biology, gene editing / cellular engineering. Founded on my exceptionally strong molecular background and skill-sets, I seek to bridge between molecular and ‘omics’ studies to latest translational, mathematical modeling.